Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWERMENT: Empagliflozin vs sitagliptin in HFpEF with type 2 diabetes
jRCTs071180091Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Peak VO2 change from baseline to 12 weeks. Started Dec 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCTs071180091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180091.